Dr. Høngaard Andersen holds a B. Sc. in Chemistry, M. Sc. in Biochemistry and is Dr. of Medicine. He has extensive drug discovery and development experience from Novo Nordisk A/S and Lundbeck A/S. He has been involved in the discovery and development of several drugs on the market (e.g., Norditropine Simplex, Victoza, Trintellix/Brintellix, Cipralex). Currently, Dr Høngaard Andersen is Operational Partner at Forbion, one of the largest venture funds in EU. Dr. Høngaard Andersen has founded or co-founded several biotech companies e.g. Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics, Prexton Pharmaceuticals Edvince AB. Dr. Høngaard Andersen was involved in Innovative Medicines Initiative (IMI) from the beginning in 2003 and was chairing the industry side of IMI from 2009 – 2014. Dr. Høngaard Andersen has founded Innovation Fund Denmark in 2014 and was Managing Director until May 2019. Dr. Høngaard Andersen is currently Chairman of the Board of Directors in Edvince AB and member of the Board in Immunovia AB, Monsenso A/S. He is a citizen of Denmark.
Professor Edvinsson is a leading expert in the field of cerebral circulation. He is world-recognized for his work on vascular innervation and receptor regulation. His extensive research is a major contributor to the current knowledge about the roles of the cerebral vasculature in health and diseases such as stroke and primary headaches. He is the director and founder of the Glostrup Science Park at Copenhagen University Hospital and Professor in Internal Medicine, Faculty of Medicine, and senior consultant in internal medicine, University Hospital SUS Lund. He has received numerous honors and awards including Director and President, International Headache Society; Member, Steering Board, European Headache Federation; Honorary Doctorate, University of Xián, China; Lifetime Achievement Award, American Headache Society. He was recently awarded the Lundbeck Foundation’s prestigious Brain Prize 2021. He is a citizen of Sweden.
Dr. Duvold holds a PhD degree in chemistry from Université Louis Pasteur. He has extensive experience in the biotech and the pharmaceutical industries including SVP and head of research, early development and patent at LEO Pharma, CEO and co-founder of Aker Biopharma, CEO of Coegin Pharma. He recently served as EVP and later CEO of Innovation Fund Denmark. Dr. Duvold is also CEO and Board member associated partner at Copenhagen Institute for Futures Studies and has comprehensive experience in university collaborations. He is a citizen of Denmark and Norway.
Dr. Adami has a background as medical doctor, master of public health and professor in clinical epidemiology. She has many years of academic experience from Uppsala University, Karolinska Institutet, Harvard University and National Institutes of health. Dr Adami has had several leading positions in the life science sector where she has served as Director and Head of Health Division at the Swedish Governmental Agency for Innovation Systems (VINNOVA) and as commission leader for the Swedish Government. She also has vast experience of board work in both the public and private sector. Dr. Adami is currently president of Sophiahemmet University. She is a citizen of Sweden.
Jesper Kihl holds degrees in Chemical Engineering, Regulatory Affairs, Business Administration and Clinical Psychology, and has more than 40 years’ experience within life science and medtech, mostly from leading positions. He spent 14 years at LEO Pharma as Vice President Global Regulatory Affairs. Prior to that, he served at Novo Nordisk for 22 years, active in manufacturing, quality, development, marketing, sales and logistics. Jesper Kihl is and has been a member of several Boards and Advisory Boards, and works with funds, universities and other institutions. He is a citizen of Denmark.
Mr. Martin Møller holds a degree in humanities. He has broad and deep experience in the international healthcare industry from more than 20 years at McKinsey & Company, a global management consultancy, where he was a leader in the Life Sciences Practice until 2021. In that role, he advised companies on strategy, transformation and business development, as well as product development, launch and commercialization. Martin Møller has worked with many segments of the life science industry and across geographies. His experience includes both working with companies in the rapid growth phase and more established companies with global operations. He is now a professional board member, advisor and investor. He is a citizen of Denmark and the US. Mr. Møller is currently Chairman of the Board of Scandion Oncology A/S and board member of Immunovia AB and Rehaler A/S. He is a citizen of Denmark and the US.
Dr. Larsen holds a PhD in neurobiology, and has 10 years of experience in drug discovery as well as 15 years of experience in drug development from Lundbeck, ALK and Klifo. She has primarily worked within the field of neurodegenerative disorders in both drug discovery and drug development, with experience throughout the whole value chain from target discovery to filing a market authorization application, including experience in Phase I, II, and III. At ALK, Stine developed and executed a large pediatric study in allergic asthma. At Klifo, she was the head of the Pharmacovigilance Department. Stine Larsen’s passion is to use her molecular understanding of disease biology and the drug being tested as the basis for designing clinical development programs, with a view to highlighting drug efficacy. She is a citizen of Denmark.
c/o Medicon Village
223 81 Lund, Sweden
Tore Duvold, CEO